What the Ensifentrine FDA Approval Means for COPD
In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.
CATALYST Raises Red Flag on Hypercortisolism in Type 2 Diabetes, with Ralph DeFronzo, MD
Ralph DeFronzo, MD, discusses the results of the first phase of the CATALYST trial and how results should influence the care of patients with difficult-to-treat type 2 diabetes.
Signs and Symptoms of Connective Tissue Disease
Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.
What to Know About Cannabis Use and Diabetes, with Halis Akturk, MD
Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.
Timothy Garvey, MD: Drivers of Differences in Weight Loss with Incretins Based on Diabetes Status
Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.
What Makes JAK Inhibitors Safe in Dermatology
Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.
Potential JAK Inhibitor Combination Regimens in Dermatology
Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.
Therapies in Development for Hidradenitis Suppurativa
Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.
"Prednisone Without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.
The JAK Inhibitor Safety Conversation
Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.
Jonathan Silverberg, MD, PhD, MPH: LEVEL UP Aids in Clinical Decision-Making for Atopic Dermatitis
Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.
Systemic Therapies Coming Soon for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD
This interview with Silverberg featured a discussion of new data on systemic therapies for various dermatologic conditions.
Kaitlin Mayne, MBChB: Impact of Multimorbidity, Polypharmacy on Benefits of SGLT2i in CKD
Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.
Mona Shahriari, MD: Evolving Role of Nonsteroidal Topicals in Plaque Psoriasis
Mona Shahriari, MD, discusses the evolving role of nonsteroidal topical options the management of plaque psoriasis.
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care
Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.
Awaiting FDA Decision on MDMA-Assisted Therapy, with Bessel van der Kolk, MD
Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Van der Kolk discusses the long-term outlook of MDMA in patients with PTSD and what further outcomes he'd like to see explored in the space.
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy
At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.
Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia
Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.
Why Are Adult ADHD Cases Climbing?
Julie Thomas, MS, DMSc, PA-C, discusses why ADHD cases may go undetected into adulthood, and the methods to treat such patients.
Robert Rosenson, MD: RNAi Therapies Show Promise in Mixed Hyperlipidemia
Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.
Deepak Sambhara, MD: Impact of CRT on Aflibercept 8 mg Outcomes in DME
Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.
Optimizing Diabetes Therapies with New Classifications
Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains how the adoption of 5 new diabetes subtypes may foster precision care.
Jonathan Barratt, MD: Matching-Adjusted Indirect Comparisons of eGFR slopes for IgAN Treatments
Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.
